客户临床管线渗透顺利，经营效率稳步提升

!"$%& z($z()*%&!"#$%&&'()*!"ƒ$&ƒ$E(ƒ$123456789:<=>?@ABCDEFGGFHHEEGGGHIJKLCEFGGGMEGENMOPCQiSjiUVWXYZiX[U\Z]Z^_ -`abcdefghCINDASECURITIESCO.,LTDijklmnokpqr9Bs1BtOAC100031 +fl-./0123456789:;<= !0!3$0%&03I 6789:;<=2022>>?@ABC>DEFG2.94HIByoy+38%B JKLMN1.05HIBOPQR74%BSTJKLMN0.89HBOPQU 79%VWMX63.97%BOPYZ2.79pctBJKLMX35.71%BOPQU7.31 pctB[M\]^_`aV bc8 defghijkQUBlmQnRoVpqrstuBdefghvwFG2.03HIx+59.18%yBWMXz74.32%BOPQR0.50pctx[S|21>def]~ËÄghBÅFGOPQU72.31%BWMX`a3pctyÇCDMOghvwFG0.91HIx+7.01%yBWMX40.99%BOPQU1.94pctVpÉÑtuBlmQnÖÜRoBvwámFG0.51HIBFGàPâz17.46%Bä2021>QUã15åBlçméèêíìBHEK293xOPM-293CD05MediumydefîïñFDAóDMFòôBröõú]ùû_`aV Rü†<°GB¢£sij§•B¶ß®X©®`aVDEijRü† <°GB™´i¨©fiÆØ¿±∑f ¥Bµ<qrΩÁ§Q∞ÚØ¿ ±∑Bªº§qr™hæOPM-CHOø¿¡mRNA¬Ø™hƒBégéèó«»…ìcB†<¢£ 3300ÀBOPQU68.6%B¢£Xz11.3%VOÃB22>ä21>ÕŒ¡œ–¡†<¢X—“YZâ1.55pctB”¢£ X‘’âz31.63%V÷©â1400ÀóMïFGBfiMNsƒ⁄ÖÜB [¤‹MïFGiø21>xâz489ÀIyBÅJKLMX›’z 32.65%BOPQU4.3pctB¢£œfiäzºflV ‡·éè‚„œ‰ÂÊÁMB©ËÈ⁄DEqrijÍÎVÏÌ2022 >ÓB‡·éèÔS©111ÒîÚÛÔÙıˆØr†<œ‰˜£DE¯ ˘defqrB”Ô˙˚‚„¸70Òx+24y¡‚„I˝19Òx+11y¡ ‚„II˝7Ò¡‚„III˝14Òx+2y¡˛g•1ÒV‡·éèó‚„ùˇB©ËÈ⁄DEdefFGÍÎV!ótuBwffi#$sz¸séè`%&'¡$˝CDMOq\(‹)*$¸sdef©Ëz$s+q ,-Bvwfiéèó.?/ÛB©Ë˜DE´i0qdef12É3V [M›48ffi6‡·é蜉7$ªù¡defqr89:;<=¡¶ß®Xij§•B>?›’2023-2025>FG¬@z4.12/5.83/8.11HIBQnz39.8%/41.5%/39.2%BJKLMN¬@z1.51/2.14/2.91HIBQnz43.7%/41.6%/35.5%VfiA2023-2025>EPS¬@z1.85/2.62/3.55IBPEz60/42/31åV BCDE8§r†<ù?:F›˝ÇéèGˇ:F›˝B§QHIÎ:F›˝BJKLMRNBCV Ø"#$%&'()*+(67.) 2021A213 2022A294 2023E412 2024E583 2025E811 /01YoY% 70.2% 38.4% 39.8% 41.5% 39.2% 23456789 60 105 151 214 291 (67.)/01YoY% 416.9% 74.5% 43.7% 41.6% 35.5% :81% 59.9% 64.0% 63.9% 64.0% 63.3% 7;<*=1ROE% 10.7% 4.8% 6.5% 8.4% 10.2% EPS(>Š)(.) 0.98 1.54 1.85 2.62 3.55 @A1P/E(B) 0.00 67.01 59.67 42.13 31.08 @71P/B(B) 0.00 3.87 3.87 3.54 3.18 ;CDEF7GHIJKLMNOPQR;SffiU2023V03W31X*Yffi ;<Z[\]^:67.89\]^:67. _`Va2021A2022A2023E2024E2025E_`Va2021A2022A2023E2024E2025E cd;<4411,8691,9942,2392,590'()*+213294412583811 ef;g3101,5061,5691,7271,964'(hi85106149210298 j*kl 0 1 0 0 0 '(mgn op 1 1 2 3 4 j*qr427696136189stuv1014212636 Qwqr12346xyuv41466282109 ze34446389127MNuv2033415573 [|54240263283304#$uv0-11-37-41-45 ]cd;<306479510515507~7ÄÅÇ ` 00000 0ÉSÑÖ ; 0 0 0 0 0 Ö;7*= 4 4 0 0 0 Üá;<86117135128109[|47346 äã;<4240506070'(8964116178252341 [|177322325327328'(å*ç44000 ;<)`7472,3482,5042,7543,09689)é68119178252341 cdZ[968993126175èGm814253548 êÉÀr402000078960105153217294 jwkl00000íìSîÄ jwqr 13 21 30 42 60 23456 789 60 105 151 214 291 = 00223 EBITDA EPS(ïV)(.) 93 138 176 252 339 0.98 1.54 1.85 2.62 3.55 [|42486384114 ]cdZ[ 89 74 74 74 74 0ÉÀr1811111111 [|7163636363ñgcó\]^:67. Z[Ç`185163166200248_`Va2021A2022A2023E2024E2025E íìSîÑ = 0 0 2 4 7 ò'ôdñ gc 115 112 174 224 293 23456 SîÑ= 5622,1852,3362,5512,84178960105153217294 Z[öSî Ñ= 747 2,348 2,504 2,754 3,096 õú>s 32 39 39 45 49 Ø"#$%&]^:67. 2021A2022A2023E2024E2025E _`Va #$uv Ö;ÄÅ 5 3 1 1 1 0 -4 -4 -4 0 'ù;gû '()*+ 213 294 412 583 811 †°70.2%38.4%39.8%41.5%39.2% à%â 2345660105151214291 789 Ö;ôdñ d [ü 21 -34 -19 -38 -50 0 3 0 0 0 ;iç¢ -99 -147 -70 -50 -40 gc-140-386-90-65-55 †°416.9%74.5%43.7%41.6%35.5%0ÉÖ;-8-3-20-15-15 :81 à%â 59.9%64.0%63.9%64.0%63.3% [| -33 -236 0 0 0 ROE%10.7%4.8%6.5%8.4%10.2% EPS(>0.981.541.852.623.55 Š)(.) £;ôdñ gc201,474-21-1-1 §*Ö; 0 1,523 0 0 0 P/B 0.00 3.87 3.87 3.54 3.18 EV/EBITDA -2.04 51.10 42.72 29.28 21.06 P/E0.0067.0159.6742.1331.08Àr4332-2000 çw8•¶ S• -2 -2 -1 -1 -1 ñgc7/ pé-61,20363158237 "#$%& <=>u12&456789:vwxyz[&|ab]~~ab]Ä@abv2016ÅÇÉÄ@ab1ÑÖÜáàu2019Åâä1ÑÖÜ6789:u2020Åãåçé2èáàu2021ÅäêëÖÜ@íìîïñóòv2022ÅÇÉ-`abuäíìôöîïõñóòv2021Åúùûü†2°1Ö[2¢]£§•1Ö[1¢/2è[1¢]ù¶ûó|ß®$©89:™4[1¢/2è[2¢ /1Ö[3¢]1a¨$©89:†21Ö[3¢u2022Åúù¶ûó|ß®$©89:™4[2¢/1Ö[2¢/2è[2¢]™4Ÿ@Æ|89:v Øì±uáàîru1¥µÈqÜqÜ◊܃ÄuwªPPC©ºtParexelæø¿¡CRO¬Ou2021ÅÇÉ-`abuƒ)CXO Ÿ@íìv Z∞«uáàîruî»…Üs ÜíìÀeàÜÕÄuijqÜÕÄ%v2021Å12ŒÇÉ-`abuœ–ƒ)º—…ÜÖÜŸ@íìv “”uáàîru‘’qÜó÷܃ÄuHÅabæ@óŠvwª+ÿ~|æøíì¬OuHGHHÅMŒÇÉ-`abuƒ)™◊Ÿ ⁄]¤‹◊Ÿ@íìv ›fiuáàîru1¥µÈqܺfl™Ü¬‡·…AƒÄuwª‚mabíìÀ™◊áà¬OuHGHHÅ„ŒÇÉ-`abuƒ)™ ‰ÂÊtî◊ÁËŸ@íìv ÈÍÎuáàîru1¥µÈqܺflÏÌÜÄuÓÔ~±ÒqÜ-0ÏÌåòƒÄuEÅabæ@óŠvwª»|abæøíì ¬OuHGHHÅÇÉ-`abuƒ)™‰ÚÛ]™‰Ùı]ˆ˜™‰]¯˘™‰˙Ÿ@íìv !"#$%&ß ß® ©™ Ǩ ÁÆ Ø_st)± ˜≈W 13911026534 hanqiuyue@cindasc.com ¥µßst)± Úñæ 15601850398 chenmingzhen@cindasc.com ¥µßstG)± 몺 18506960410 quejiacheng@cindasc.com ¥µßst ¬æø 13051504933 qiliyuan@cindasc.com ¥µßst ¿¡¬ 17687659919 luyuzhou@cindasc.com ¥µßst ¸ƒ 18340820155 weichong@cindasc.com ¥µßst •“ 15501091225 fanrong@cindasc.com ¥µßst «» 18513322185 miqiao@cindasc.com ¥µßst …  13552992413 lijia1@cindasc.com ¥µßst ÀÃÕ 15690170171 zhaolanqi@cindasc.com ¥µßst Œœ9 18810718214 ¥µßst Z“” 18735667112 wangzheyu@cindasc.com ¥îßst)± ‘’ 13718803208 yangxing@cindasc.com ¥îßstG)± ÷_ 15800476582 wuguo@cindasc.com ¥îßst _ƒº 15618358383 guopengcheng@cindasc.com ¥îßst ÿŸ 18702173656 zhuyao@cindasc.com ¥îßst ⁄¤‹ 13524484975 daijianxiao@cindasc.com ¥îßst ›fi 18721118359 fangwei@cindasc.com ¥îßst fl‡ 18717938223 yuxiao@cindasc.com ¥îßst …·“ 15026867872 lixianzhe@cindasc.com ¥îßst ‚„ 18610826885 suntong@cindasc.com ¥îßst ‰Â 1